Stan Consulting · Industry
Pharma and life sciences operators run significant paid media budgets through channels the compliance team has already approved. The structural problems in those systems are not regulatory. They are architectural.
Get the $999 Diagnostic How We WorkQuick answer
Stan Consulting provides structural diagnostics of paid acquisition and conversion architecture for pharma, biotech, specialty pharma, medical device, and life-sciences services companies. The diagnostic works within compliance boundaries the client has already established. It is not MLR consulting and not clinical regulatory work. The Conversion Second Opinion is the $999 entry diagnostic, delivered in 72 hours. Stan Consulting works with clients across the United States and internationally, including active engagements in New York, Texas, Los Angeles, Germany, and Israel. The office is in Roseville, California.
20+
Years in Paid Media
Diagnostic First
Before Any Campaign Change
HCP + DTC
Both Acquisition Architectures
$999
Diagnostic · 72-Hour Delivery
Root causes
Compliance restrictions explain some of the performance gap. They do not explain most of it. These four structural issues appear across pharma and life sciences paid media accounts regardless of therapeutic area or channel mix.
Paid campaigns run on live budgets while revised creative sits in MLR review. The account spends against assets that are pending replacement. No pause-and-resume protocol is in place. Budget burns without a commercial rationale.
Healthcare professional acquisition and direct-to-consumer patient funnels require different landing page architectures, different conversion definitions, and different attribution models. When they share the same campaign structure, neither performs at the level it would with proper separation.
Landing pages are built to pass MLR review, not to convert the visitor. Fair-balance requirements are implemented in ways that bury the primary message. The page is compliant. It does not generate the intended commercial action.
Standard conversion tracking setups break against HIPAA constraints and third-party cookie restrictions relevant to health audiences. Campaigns run without verified attribution. Spend decisions are made on incomplete data.
Structural failures
These six structural problems appear consistently across pharma and life sciences paid accounts. Each one is architectural. None of them requires a regulatory change to fix.
Brand teams restrict digital advertising further than the compliance team has required. The result is an account running well inside its approved zone, at a fraction of the commercially available reach. The diagnostic identifies where the restriction is regulatory versus where it is habitual.
An asset approved for a professional congress digital campaign gets deployed in a consumer Google Display placement. The compliance boundary was drawn for a different context. The channel mismatch creates both a performance problem and a review exposure that was not anticipated at approval.
Healthcare professional paid campaigns drive clicks to detail pages with no defined next step. The conversion event is a page visit. There is no handoff to the field force CRM, no triggered rep follow-up, and no measurement of whether the click produced a commercial outcome downstream.
Patient-directed digital advertising generates awareness-stage traffic. The funnel stops there. Post-click pages do not address the Rx conversation, insurance navigation, or patient support program enrollment. Traffic arrives and exits without a defined next commercial step.
Significant budget runs through brand awareness channels with no attribution framework that meets the compliance team's data-handling requirements. The brand team cannot report ROI. The compliance team cannot validate what patient data is being processed. Neither problem gets resolved.
Google and Meta health-category advertising restrictions apply differently by product type, audience targeting method, and geography. Accounts are built without accounting for those restrictions and then lose reach when the platform flags a targeting parameter or creative claim. The fix should have preceded the launch.
What we review
Every pharma and life sciences engagement begins with a structured review across these six areas. The audit is scoped to what the compliance team has already approved. No campaign changes are made until the diagnostic findings are delivered.
01
The channels currently running are mapped against the MLR-approved asset inventory and the compliance team's documented channel permissions. Gaps between what is approved and what is deployed are identified and ranked by revenue impact.
02
Every live paid asset is checked against its MLR approval context. Channel, audience type, and claim language reviewed for contextual fit. Assets deployed outside their approval context are flagged before they become a compliance exposure.
03
Conversion events reviewed for HIPAA compliance and platform data policy alignment. Third-party cookie dependency assessed. Attribution model reviewed for fitness in a health-audience context where standard tracking configurations are often not available without modification.
04
Every healthcare professional-facing paid placement checked against its landing page for message continuity, prescribing-information availability, and defined next commercial action. Pages where the professional arrives and has no clear path to a clinical or commercial decision are documented and ranked by traffic volume.
05
The patient-facing funnel reviewed from first ad impression through to the defined conversion event, whether that is a patient support program enrollment, a savings card download, a pharmacy locator click, or a physician-finder query. Drop-off points are identified and ranked by estimated recoverable volume.
06
The attribution model in use is reviewed against the actual data available in a health-category context. Where platform-reported conversion data cannot be validated, the gap is documented. Where a compliant alternative attribution approach is available, it is specified in the prioritized fix list.
Where budgets are lost
The same agency failures appear across pharma accounts. These are not one-off errors. They are predictable patterns that follow when diagnostic judgment is absent from account decisions and compliance is used as a reason to avoid performance accountability.
When results are below expectation, the compliance review cycle is cited as the cause. The agency does not examine whether the MLR-cleared assets are structured correctly for the channel, whether the landing page converts within its approved content, or whether the campaign architecture itself is the source of the underperformance.
The account runs at a fraction of the reach available within its compliance-approved parameters. Audience targeting is set conservatively. Bid strategies are left at defaults. Creative rotation is absent. The agency reports impression and click metrics without examining whether the account is operating at the edge of its approved reach.
Professional and consumer audiences share campaign structure, budget, and reporting dashboards. The commercial objectives of the two funnels are different. Their conversion architectures must be different. When they are not, each funnel performs at a fraction of its potential and the attribution data from each contaminates the other.
The agency reports platform-based performance metrics. The compliance team cannot confirm that the underlying data handling is permissible. The brand team cannot connect paid media spend to downstream Rx volume or patient program enrollment. The metrics exist but they do not answer the question that matters commercially.
Scope clarity
Common questions
Continue reading
Scope of work · what this is and what it is not
What this diagnostic addresses
Paid campaign architecture. Conversion tracking. Landing page message match. HCP and DTC funnel separation. Attribution model fitness. Budget allocation against channel performance data. All reviewed within whatever the compliance team has already approved.
The question is whether the system inside the approved zone is structured to perform. Most are not.
What this diagnostic does not address
Medical-legal-regulatory review. MLR consultation. FDA promotional guidelines interpretation. Clinical or safety labeling. OPDP submission advisory. IRB review of recruitment materials.
Those boundary questions belong with regulatory counsel and your MLR committee. They are decided before the diagnostic begins.
Beyond the campaign
Pharma and life sciences marketing problems are rarely only campaign problems. The channel restriction that looks like a compliance constraint is sometimes a positioning problem: the claim cannot run in the channel because the claim is too broad for the audience. The landing page that fails conversion is sometimes a medical affairs problem: the approved content brief does not address what the HCP actually needs to make a prescribing decision.
The diagnostic identifies the structural cause. In pharma, the structural cause is often at the intersection of marketing, medical, legal, and regulatory. The diagnostic does not resolve that intersection. What it produces is a prioritized fix list that names what is solvable within the marketing and paid acquisition system, and what belongs in a different room.
Organizations that have found value in that distinction tend to engage at the consulting level after the initial diagnostic. Monthly retainer engagements allow for ongoing review as campaigns change, MLR cycles complete, and compliance boundaries are renegotiated between launch windows.
Scope note
This diagnostic is not a substitute for regulatory counsel. The compliance boundaries reviewed are those your organization has already established. We identify where the marketing system underperforms within those boundaries. Regulatory boundary decisions remain with your MLR committee, legal team, and regulatory affairs function.Not sure what is broken
Start with the $999 Conversion Second Opinion. Structural diagnosis in 72 hours.
Need ongoing review
Monthly consulting from $1,500. Scoped to campaigns, compliance cycles, and launch windows.
See all formats
Five engagement formats. Diagnostic findings determine the right scope.
Diagnostic-first. Scoped to your approved channels and compliance context. Written findings in 72 hours.
See How We Work